ArticlePloS one2014
Prioritizing candidate disease metabolites based on global functional relationships between metabolites in the context of metabolic pathways.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Metabolite-disease interaction prediction based on logistic matrix factorization and local neighborhood constraints.Frontiers in psychiatry · 2023Article
- Deciphering the Core Metabolites of Fanconi Anemia by Using a Multi-Omics Composite Network.Journal of microbiology and biotechnology · 2022Article
- Identification of Therapeutic Targets for the Selective Killing of HBV-Positive Hepatocytes.Journal of personalized medicine · 2021Article
- An Inductive Logistic Matrix Factorization Model for Predicting Drug-Metabolite Association With Vicus Regularization.Frontiers in microbiology · 2021Article
- Sharing of Genetic Association Signals by Age-Related Macular Degeneration and Alzheimer's Disease at Multiple Levels.Molecular neurobiology · 2020Article
- Article
- Prioritizing chronic obstructive pulmonary disease (COPD) candidate genes in COPD-related networks.Oncotarget · 2017Article
- MetabolitePredict: A de novo human metabolomics prediction system and its applications in rheumatoid arthritis.Journal of biomedical informatics · 2017Article
- Chronic obstructive pulmonary disease candidate gene prioritization based on metabolic networks and functional information.PloS one · 2017Article
- Global Prioritization of Disease Candidate Metabolites Based on a Multi-omics Composite Network.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of key metabolites for complex diseases is a challenging task in today's medicine and biology. A special disease is usually caused by the alteration of a series of functional related metabolites having a global influence on the metabolic network. Moreover, the metabolites in the same metabolic pathway are often associated with the same or similar disease. Based on these functional relationships between metabolites in the context of metabolic pathways, we here presented a pathway-based random walk method called PROFANCY for prioritization of candidate disease metabolites. Our strategy not only takes advantage of the global functional relationships between metabolites but also sufficiently exploits the functionally modular nature of metabolic networks. Our approach proved successful in prioritizing known metabolites for 71 diseases with an AUC value of 0.895. We also assessed the performance of PROFANCY on 16 disease classes and found that 4 classes achieved an AUC value over 0.95. To investigate the robustness of the PROFANCY, we repeated all the analyses in two metabolic networks and obtained similar results. Then we applied our approach to Alzheimer's disease (AD) and found that a top ranked candidate was potentially related to AD but had not been reported previously. Furthermore, our method was applicable to prioritize the metabolites from metabolomic profiles of prostate cancer. The PROFANCY could identify prostate cancer related-metabolites that are supported by literatures but not considered to be significantly differential by traditional differential analysis. We also developed a freely accessible web-based and R-based tool at http://bioinfo.hrbmu.edu.cn/PROFANCY.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.